Advanced in Molecular Mechanisms of Atherosclerosis: From Lipids to Inflammation

Anna Meiliana\textsuperscript{1,2,*}, Nurrani Mustika Dewi\textsuperscript{2}, Andi Wijaya\textsuperscript{1,2}

\textsuperscript{1}Postgraduate Program in Clinical Pharmacy, Padjadjaran University, Jl. Eijkman No.38, Bandung, Indonesia
\textsuperscript{2}Prodia Clinical Laboratory, Jl. Cisangkuy No.2, Bandung, Indonesia

*Corresponding author. E-mail: anna.meiliana@prodia.co.id

Received date: Jun 21, 2018; Revised date: Jul 24, 2018; Accepted date: Jul 31, 2018

BACKGROUND: Atherosclerosis is a leading cause of vascular disease worldwide. During the past several decades, landmark discoveries in the field of vascular biology have evolved our understanding of the biology of blood vessels and the pathobiology of local and systemic vascular disease states and have led to novel disease-modifying therapies for patients. This review is made to understand the molecular mechanism of atherosclerosis for these future therapies.

CONTENT: Advances in molecular biology and -omics technologies have facilitated in vitro and in vivo studies which revealed that blood vessels regulate their own redox milieu, metabolism, mechanical environment, and phenotype, in part, through complex interactions between cellular components of the blood vessel wall and circulating factors. Dysregulation of these carefully orchestrated homeostatic interactions has also been implicated as the mechanism by which risk factors for cardiopulmonary vascular disease lead to vascular dysfunction, structural remodeling and, ultimately, adverse clinical events.

SUMMARY: Atherosclerosis is a heterogeneous disease, despite a common initiating event of apoB-lipoproteins. Despite of acute thrombotic complications, an adequate resolution response is mounted, where efferocytosis prevents plaque necrosis and a reparative scarring response (the fibrous cap) prevents plaque disruption. However, a small percentage of developing atherosclerotic lesions cannot maintain an adequate resolution response, which leading to the formation of clinically dangerous plaques that can trigger acute lumenal thrombosis and tissue ischemia and infarction.

KEYWORDS: atherosclerosis, oxidative stress, inflammation, efferocytosis, foam cells, thrombosis

Abstract

BACKGROUND: Atherosclerosis is a leading cause of vascular disease worldwide. During the past several decades, landmark discoveries in the field of vascular biology have evolved our understanding of the biology of blood vessels and the pathobiology of local and systemic vascular disease states and have led to novel disease-modifying therapies for patients. This review is made to understand the molecular mechanism of atherosclerosis for these future therapies.

CONTENT: Advances in molecular biology and -omics technologies have facilitated in vitro and in vivo studies which revealed that blood vessels regulate their own redox milieu, metabolism, mechanical environment, and phenotype, in part, through complex interactions between cellular components of the blood vessel wall and circulating factors. Dysregulation of these carefully orchestrated homeostatic interactions has also been implicated as the mechanism by which risk factors for cardiopulmonary vascular disease lead to vascular dysfunction, structural remodeling and, ultimately, adverse clinical events.

SUMMARY: Atherosclerosis is a heterogeneous disease, despite a common initiating event of apoB-lipoproteins. Despite of acute thrombotic complications, an adequate resolution response is mounted, where efferocytosis prevents plaque necrosis and a reparative scarring response (the fibrous cap) prevents plaque disruption. However, a small percentage of developing atherosclerotic lesions cannot maintain an adequate resolution response, which leading to the formation of clinically dangerous plaques that can trigger acute lumenal thrombosis and tissue ischemia and infarction.

KEYWORDS: atherosclerosis, oxidative stress, inflammation, efferocytosis, foam cells, thrombosis

Introduction

The burden of cardiovascular disease (CVD) has been risen to be a leading cause of morbidity and mortality despite the existence of statin and other preventive strategies to resolve it.\textsuperscript{(1,2)} Simultaneously, many clinical researches had been performed to unravel the mechanisms and pathophysiology of atherosclerosis along with the clinical complications. These let us discover the development of new therapeutic approaches to combat CVD which is accompanied by so many advances and surprises.\textsuperscript{(3)}

Gimbrone and García-Cardeña described the endothelial cells as a gatekeeper with barrier function, emerging the defender of vascular homeostasis.\textsuperscript{(4)} Disturbances in antithrombotic, profibrinolytic, anti-inflammatory and antioxidant properties of the normal endothelium lead to endothelial dysfunction and impairment of its vasodilator capacity.

Inflammation is entangled with traditional and emerging risk factors of atherosclerosis and its complication as a linked target pathways for developing therapies. Current large-scale study is applying weekly administration of low-dose methotrexate (MTX) or a monoclonal antibody.
We know that one size fits all approach is nowadays clinical application.(3) bring those hypotheses from basic research to advance pharmacogenomic determinants of the response to therapies usefulness of genetic information in risk prediction and inflammation are affecting not only atherosclerosis but also influence autoimmune diseases.(3)

The ascertainment of high-density lipoprotein (HDL) functions (such as cholesterol efflux potential), HDL particle number and therapeutic approaches that increase these variables faces challenges from disappointing results in many clinical studies and Mendelian randomization analyses.(8) Other approaches focusing on increasing the HDL function, using HDL mimetics to reverse transporting cholesterol or apolipoprotein A1 (apo A1) infusion, are also need to be reconsidered.

Recent studies on triglyceride-rich type lipoproteins and its pathogenicity have revitalized the enthusiasm for finding apolipoproteins V, apolipoproteins and C3, Angptl3 and Angptl4 as new therapeutic triglycerides targets or perhaps more specifically cholesterol-rich remnant lipoproteins.(8,9) Genome-wide association studies and Mendelian randomization analyses brought up Lipoprotein (a) (Lp(a)) as a causative agent in atherothrombosis,(10) Another study found the role of noncoding small RNAs (micro-RNAs) as the power switch on atherosclerotic progression and regression as well as regression and lipid metabolism, which has opened entirely new vistas on the molecular pathways that control this disease.(11)

Then any availability of validated genetic markers proposes the possibility for applied risk stratification and personalized or precision medicine targeting therapy mode.(10,11) Paynter, et al., proposed about the usefulness of genetic information in risk prediction and pharmacogenomic determinants of the response to therapies for atherothrombosis.(12) More studies were needed to bring those hypotheses from basic research to advance clinical application.(3)

We know that one size fits all approach is nowadays need to be developed into a smarter design. The goal of precision medicine in the future management of atherosclerotic risk in our patients could be achieved by using biomarkers and genetic information rationally to classify target therapies toward those who will most likely to benefit from the treatment.(13,14)

---

**Lipoproteins, Apolipoproteins and Atherosclerosis**

Today, it is no longer a hypothesis, but an established fact, that increased plasma concentrations of cholesterol-rich apolipoprotein-B (apoB)-containing lipoproteins are causatively linked to atherosclerotic CVD and that lowering low-density lipoprotein (LDL) concentrations with statins and non-statin reduces atherosclerotic cardiovascular events in humans.(15-20) After decades of research, however, there is now a large body of evidence to support the response-to-retention hypothesis, which proposed that the key initiating event in atherogenesis is the retention, or trapping, of cholesterol-rich apoB-containing lipoproteins within the arterial wall. The retained lipoproteins and their byproducts provoke a series of strikingly maladaptive local responses that cause plaque initiation, growth, and evolution.(21)

The response-to-retention hypothesis, which was drew on work from the 1940s to the 1980s, shows that lipoproteins can interact with proteoglycans of the arterial wall.(22-25) Lipids and apoB are accumulated at lesion-prone sites before gross morphological changes occur.(26-29) Retention of apoB-lipoproteins is seen throughout the progression of atherosclerosis. The consequences of the retention of apoB-lipoproteins include, not only an accumulation of lipid, but also prolonged exposure of these particles to local enzymes and other factors within the vessel wall. The retained and modified apoB-lipoproteins trigger cellular responses within the artery wall that accelerate further lipoprotein retention and lesion development.(30-32)

In earliest atherogenesis, negatively charged proteoglycans in the extracellular matrix of the arterial intima bind and trap apoB-lipoproteins via electrostatic interactions with specific positively charged aminoacly residues in the full-length hepatic form of apoB, apoB100 (residues 3359–3369) (33), and in the truncated intestinal form, apoB48 (residues 84–94) (34). Moreover, apoB48-lipoproteins typically contain numerous molecules of apoE, an apoprotein that has a proteoglycan-binding domain almost identical to the proteoglycan-binding sequence in apoB100. Proteoglycans are negatively charged due to the sulfate and carboxylic acid groups in their GAG side-chains. Lipoproteins normally flux into and out of the arterial
The molecular mediators of this trans-endothelial movement of lipoproteins remain incompletely characterized. Recent evidence has suggested roles for caveolin-1 (36,37) and the scavenger receptor class B type I (SR-BI) (38). Following retention of cholesterol-rich apoB-lipoproteins within the artery wall, the lipoproteins have been shown to undergo several modifications with important biological consequences (Figure 1).

Aggregated apoB-lipoproteins are avidly taken up by macrophages (30,39) and by vascular SMCs (40) and lead to foam-cell formation. These processes stimulate the release of proatherogenic factors that induce the synthesis of proteoglycans with enhanced affinity for atherogenic lipoproteins.(30,39) In addition, monocyte/macrophages recruited into atheromata secrete proretentive enzymes, notably lipoprotein lipase, sphingomyelinase and PLA2, that accelerate further retention of atherogenic lipoproteins.(21)

Key enzymes implicated in apoB-lipoprotein retention, aggregation, and atherogenesis include the secretory sphingomyelinase (S-SMase), lipoprotein lipase, and the non-pancreatic secretory group V phospholipase-A2 (PLA2-V).(30,41-45) These enzymes, particularly lipoprotein lipase, are bridging between LDL and proteoglycans independently of the physical state of apoB and thereby cause a shift in the retentive mechanism from a low-affinity process (apoB-GAG binding) in the pristine arterial wall to a high-affinity process (lipoprotein-GAG binding) in an established atheroma. This shift in retentive mechanism has direct clinical consequences. A lifetime plasma LDL cholesterol concentration of 80 mg/dL will almost always protects from atherosclerosis (46), but the pre-existing plaques will grow if the LDL-cholesterol is 80 mg/dL (47).

In the context of the response-to-retention hypothesis, roles for HDL in every step have been hypothesized. (48) Those roles include interfering with the irreversible binding of plasma LDL to arterial wall proteoglycans (49-51), blocking SMase-induced aggregation of LDL (52,53), removing toxic lipids and resolving the maladaptive inflammatory infiltrate (54-58). Along these lines, the apoA-I mimetic peptide 4F was recently shown to block SMase-induced LDL aggregation and the increase in binding of the modified LDL particles to human aortic proteoglycans. (59) In contrast, abnormal HDL or apoA-I within the arterial wall may have adverse effects.(53,60-62) Using our extensive knowledge of the pathogenesis of atherosclerosis, we can now reclassify nearly all epidemiologic risk factors into causative agents, exacerbating factors and bystander phenomena.(63) Causative and exacerbating factors are targets for therapy, meanwhile bystander phenomena are not.
Oxidative Stress, Inflammation and Atherosclerosis

Key steps in the atherosclerosis process include the accumulation and oxidation of LDLs by reactive oxygen species (ROS) within the artery wall accompany with persistent inflammatory process via infiltration of monocyte-macrophages, forming foam cells on uptake of oxidized LDL (ox-LDL). This process sooner or later can result in rupture or erosion of the arterial wall, forming thrombus and subsequent platelet aggregation called atherothrombosis, which resulting in blood flow occlusion and downstream cellular damage. The involvement of ROS in atherothrombosis process is including nitric oxide (NO) inactivation or NO synthase inhibition and platelet activation via overexpression of platelet eicosanoids and platelet NO inhibition, which finally contribute to the arterial dysfunction.(64,65)

Besides LDL, sphingolipids are also proven to have a potent biological effects in atherosclerotic process. Ceramides are a group of sphingolipids generated from hydrolysis of sphingomyelin by sphingomyelinases, neutral sphingomyelinases, and acidic sphingomyelinases (A-SMase). By the activation of sphingomyelinases, ox-LDL increases the production of ceramides.(53,66) Then sphingomyelinase-dependent hydrolysis of LDL–ceramides become a potential pathway for ceramide accumulation in atherosclerotic plaques.(53) Compared to healthy vascular tissue, glycosphingolipids, such as glucosylceramide and lactosylceramide, which are generated from ceramides have also been found higher in human atherosclerotic plaque.(67,68) Both lactosylceramide and ceramide through the action of neutral sphingomyelinase were involved in cell apoptosis (69-71), but lactosylceramide has been suggested to contribute to plaque formation by stimulating cell proliferation in human aortic smooth muscle cells (72,73). Not only associated with, but also suggested to induce plaque inflammation and instability, sphingolipids especially glucosylceramide open up opportunities to be a novel therapeutic targets.

Lipid rafts, microdomains, or nanodomains, different in sizes from 5- to 500-nm-diameter structures, could be highly ordered formed regularly from glycerophospholipids, sphingomyelin and FC, but not cholesteryl ester (CE). (74-76) Membrane rafts are small heterogeneous, highly dynamic, sterol- and sphingolipid-enriched domains that compartmentalize cellular processes.(76) They are detergent-resistant membrane complexes rich in FC. FC serve as the raft stabilizer through hydrophobic binding to the other components. Lipid raft commonly present in two types, planar lipid raft and invaginated one, with caveolar or little cave whose structure depends on the caveolin proteins that are unique to caveolae. Cholesterol is an essential component of both lipid rafts and caveolae.(77-81)

To maintain lipid raft, cells require FC. Excess FC for this purpose will be stored in the cytoplasm as CE. When the influx of cholesterol is greater than the outflow, the accumulation of CE droplets and foam cell formation occurs. Otherwise, loss of foam cell cholesterol will occur. Thus, high value of EC/total cholesterol ratio implies cell progression, whereas a low value implies foam cell regression.(82) Lipid raft must be carefully regulated so the microdomains or nanodomains are able to provide a platform for organizing the signaling of many receptors and proteins, including the B-cell receptor, T-cell receptor (83-85) and major histocompatibility class receptors (86,87). The cholesterol used to form and maintain lipid raft can be obtained from exogenous sources, such as lipoproteins, especially LDL, or from endogenous cellular synthesis via the mevalonate pathway in the endoplasmic reticulum followed by transport to the plasma membrane, or from the intracellular lipid droplets.(88,89) From lipid droplets, cholesterol will move out with help of extrinsic signals promoting the hydrolysis of CE by cholesterol ester hydrolases.(90,91) FC also can be used for cellular membrane maintenance, unless it will be moved to a substrate pool for export via ABCA1. (92,93) The membrane cholesterol that regulates lipid raft composition, controlled by ABCA1 under the regulation of the liver X receptor.(94)

Modified lipoproteins, such as ox-LDL, enhance endothelial damage that trigger leukocyte recruitment, which eventually fail to clear lipoproteins, undergo cell death, and contribute to inflammation. Ultimately, growing lesions will lead to vessel occlusion and subsequent ischemia or (arterial) thrombosis.(95,96) After long time been denied, neutrophils and their specific contribution in atherosclerosis pathophysiology, recent studies present substantial evidences about the actions of neutrophils in early and established human and murine atherosclerotic lesions.

Suicidal neutrophils expel become neutrophil extracellular traps (NET), which consist of a complex structure of nuclear chromatin and proteins of nuclear, granular and cytosolic origin. They have a net-like structures which also found in atherosclerotic lesions and arterial thrombi in humans and mice. Functionally, NET can induce pro-inflammatory immune response via activation
of endothelial cells, antigen-presenting cells and platelets. Thus, NET not only presents in plaques and thrombi but also plays a causative role in triggering atherosclerotic plaque formation and arterial thrombosis in any stage of diseases progression, especially where there are high local concentration of pro-inflammatory effector molecules.(97) The present neutrophil-derived proteases and ROS lead to plaque destabilization.(98-100)

Atherosclerosis is a chronic lipid-driven, maladaptive and non-resolving inflammatory disease of the vessel wall. Over several decades, atherosclerosis progresses in indolence and silence, eventually resulting in the formation of a life-threatening, rupture-prone atherosclerotic plaque. (101-103) In brief, the disease is triggered by subendothelial retention of infiltrated LDL into the intimal space. The accumulated LDL undergoes oxidation and aggregation in the intima, presenting a source of chronic stimuli that instigate and propagate an innate immune reaction. This includes the recruitment, homing, migration and differentiation of monocytes into macrophages that avidly phagocytose modified cholesterol, secrete pro-inflammatory cytokines, enzymes and ROS and eventually undergo cell death. Together, these processes and the defective clearance of the dying cell propagate the inflammatory response, forming a vulnerable atherosclerotic plaque. The key characteristics of a vulnerable plaque include a very thin fibrous cap encapsulating acellular necrotic core regions, lipid-laden macrophages and T lymphocytes and sometimes, intraplaque hemorrhage.(104) Figure 2 shows macrophage apoptosis, autophagy and necroptosis in atherosclerosis.

Necroptosis is a new term for a type of programmed necrosis besides apoptosis and autophagic. Current findings demonstrate that macrophage necroptosis directly contributes to necrotic core formation and plaque instability. Pro-resolving mediators have been shown to promote the inflammation resolution and enhance efferocytosis, thus

Figure 2. Macrophage apoptosis, autophagy and necroptosis in atherosclerosis.(105) (Adapted with permission from Wolter Kluwer Health).
ECD manifest as the earliest detectable changes within the arterial wall.

orchestration of acute and chronic inflammatory reactions, thrombosis, local vascular tone and redox balance, also the functional phenotype, that regulating hemostasis and a constellation of various non-adaptive alterations in the pathobiology of atherosclerotic CVD. ECD covers covering areas of the arterial vasculature contributes in Endothelial cell dysfunction (ECD) on the lesion-prone atherosclerosis and promote plaque stability.(105) will provide novel therapeutic opportunities to resolve atherosclerosis (apoptosis, necroptosis and efferocytosis) of the mechanisms that regulate macrophage death in atherosclerotic lesion.(105) Improving our understanding a role in impairing efficient efferocytosis then progress the 'don't eat me' signal cluster of differentiation (CD)47 plays decrease plaque vulnerability. Otherwise, the canonical ‘don’t eat me’ signal cluster of differentiation (CD)47 plays a role in impairing efficient efferocytosis then progress the atherosclerotic lesion.(105) Improving our understanding of the mechanisms that regulate macrophage death in atherosclerosis (apoptosis, necroptosis and efferocytosis) will provide novel therapeutic opportunities to resolve atherosclerosis and promote plaque stability.(105)

Endothelial, Vascular Smooth Muscle Cells and Atherosclerosis

Endothelial cell dysfunction (ECD) on the lesion-prone covering areas of the arterial vasculature contributes in the pathobiology of atherosclerotic CVD. ECD covers a constellation of various non-adaptive alterations in functional phenotype, that regulating hemostasis and thrombosis, local vascular tone and redox balance, also the orchestration of acute and chronic inflammatory reactions within the arterial wall.

ECD manifest as the earliest detectable changes on lesion-prone areas of the arterial vasculature in atherosclerotic lesion progression, in form of focal permeation, trapping, and physicochemical modification of circulating lipoprotein particles in the subendothelial space.(106-108) These pathogenic sequence commenced by selective recruitment of circulating monocytes from the blood into the intima.(107-113) They differentiate into macrophages and internally modified lipoproteins become foam cells, endothelium and macrophages will be activated in elaboration with multiple chemokines and growth factors, and induce the nearby smooth muscle cells (or their precursors) proliferation and extracellular matrix components synthesis within the intimal compartment, finally generating a bromuscular plaque.(114)

Developing lesions involve a continuous structural remodeling, which result in fibrous cap, overlying a lipid-rich, necrotic core consisting of oxidized lipoproteins, cholesterol crystals and cellular debris. Matrix remodeling and calcification varying degrees also play a role in this complicated plaques, along with a rich population of inflammatory cells (activated macrophages and T cells, natural killer T cells and dendritic cells), modulating the endothelial proinflammatory phenotype and proteolytic modification of its extracellular matrix component, provide the plaques’ structural instability,(115-117) When the plaque is unstable or vulnerable, frank plaque rupture, with luminal release of the highly thrombogenic contents of the necrotic core, an atherothrombotic occlusion could be triggered.(118-121) Evidently, superficial intimal erosions without plaque rupture also make a consequence of significant clinical sequelae, suggested due to endothelial cell apoptosis, with localized endothelial denudation and the triggering of thrombus formation.(4,122)

By this angle, the vascular endothelium can be regarded as a dynamically adaptable interface distributed organ, and at individual cell level, an integrator of the local pathophysiological milieu. Thus, dysfunction endothelial certainly alter its normal functional phenotype non-adaptively, entangle the regulation of hemostasis and thrombosis (123), local vascular tone (124) and redox balance (125), also induce the orchestration of acute and chronic inflammation (124). Thus, the term endothelial cell dysfunction was proposed into the mainstream of atherosclerosis research (126,127), and the molecular manifestations of ECD began to be characterized in detail. (117,121,124,128)

Several studies documented that Kruppel-like factor 2 (KLF2) expression in endothelial cells promotes an anti-inflammatory, antithrombotic endothelial phenotype, due to its antagonism of the nuclear factor kappa-B (NF-kB) pathway.(129) KLF2 regulates the functions of other endothelial cells, making it important for atherogenesis, including endothelial barrier function (130), metabolism (131) and the release of miRNAs via the shedding of endothelial microvesicles (132). It also stimulates the production of several autocoids, including NO and C-type natriuretic peptide, which were found to be deficient in dysfunctional endothelium in vivo.(133) Study showed that mice genetically deficient in KLF2 enhanced atherosclerotic plaque formation compared to wild-type controls.(134)

Nuclear factor erythroid 2-related factor-2 (Nrf2), activated by atheroprotective flow in cultured endothelial cells, via the phosphoinositol 3-kinase/Akt and extracellular signal-regulated protein kinase 5 pathways, counted to have an atheroprotector properties. Nrf2 controls a subsequential of target genes that play a role in the regulation of intracellular redox balance, as well as resistance to extracellular oxidant stress.(135-137) Nr2 in vivo expressed differentially in those relatively atherosclerosis-resistant regions of the vasculature, suggesting its pathophysiological relevance. (135,138)

Current studies reported the independent act of KLF2 and Nr2 in the activation of flow-mediated gene expression, with a requirement for KLF2 expression for full activity of Nr2 antioxidant vasoprotection-mediated.(139,140) These 2 transcription factors are pointed as master regulators of the
Molecular insights on atherosclerosis progressive pathways, and is reported to have an important role in regulating many pathophysiological processes, such as cellular adhesion, proliferation, lipid uptake and efflux, also generation of inflammatory mediators. The appreciation of miRNAs detection extracellularly including in circulating blood make a hike in its potential as new tool for diagnosis, prognosis, or in response to cardiovascular therapeutics. (11)

MiRNAs are a small (~18–24 nucleotides), evolutionary conserved, single-stranded noncoding RNAs that regulate >60% gene expression, either reducing protein expression by blocking mRNA translation and by promoting mRNA degradation at the post-transcriptional level by typically binding to the 3′-untranslated region (UTR) of specific target mRNA sequences, using a conserved ≈7–8 nucleotide seed sequence. (148–152) Moreover, one miRNA can bind to and regulate >1 target, even as a part of the same signaling pathway, also can harbor several distinct miRNA-binding sites within its 3′-UTR, adding multiple levels of regulation. Recent studies reported of LDL and HDL abundance and function controlled by miRNAs, have greatly expanded our understanding of the regulatory circuits governing plasma lipoprotein levels.

MiR-148a is negatively regulating LDL-C plasma levels by targeting the LDL receptor (LDLR) and is showed to increase the clearance of circulating labeled LDL and decrease plasma LDL-C levels. (153,154) Some miRNAs, such as miR-33 (155-159), miR-758 (160), miR-26 (161), miR-106 (162), miR-144 (163,164), miR-128-118 and miR-148a (154), play role in regulating HDL biogenesis and cholesterol efflux by controlling the levels of plasma HDL-C and the reverse cholesterol transport pathway by targeting ATP-binding cassette transporter (Figure 3). ABCA1 plays a central role in these processes by controlling cholesterol efflux across the cell membrane onto lipid-poor apoA1 (155), and mediate both hepatic HDL biogenesis and the removal of excess cholesterol from peripheral cell including macrophages in atherosclerotic plaques.

The cholesterol homeostasis in macrophages is maintained by the balance between cholesterol uptake, endogenous synthesis, esterification/hydrolysis and efflux. miR-27a/b, which is involved in this lipoprotein homeostasis, regulates the cholesterol in macrophage via genes involved in cholesterol esterification (ACAT1), uptake (LDL and CD36), and efflux (ABCA1). (165) While miR-125a-5p and miR-146a decrease lipid uptake and cytokine release in ox-LDL-stimulated macrophages, via oyster binding protein-like 9 and toll-like receptor (TLR)4 genes, respectively. (166,167) Furthermore, miR-

### MicroRNA and Circadian Control in Atherosclerosis

Both immune and non-immune cellular constituents of the vessel wall were involved in many stages of the pathogenesis of atherosclerotic lesion formation. Over decades many studies strive to uncover any key signaling and molecular regulatory pathways involve in the plaque initiation and progression. MiRNA provides novel
155 plays a role in macrophage foam cell formation by negatively regulates macrophage inhibitory factor, via the transcriptional repressor HMG box-transcriptional protein 1, a protein known to increase the uptake of ox-LDL by macrophages.\(^{168}\)

Circulating miRNA can be detected in peripheral blood, saliva and urine, so their expression may be harbingers of a range stages of CAD from subclinical atherosclerotic disease to acute coronary syndromes.\(^{11}\) miRNAs may have enormous effects on biological pathways, cell function and homeostasis in the vessel wall, liver and periphery. Experimenting a MiRNA mimics or inhibitors may offer an attractive therapeutic approach for atherosclerotic disease in specific stages and the management of its complications.

Circadian rhythms refer to 24 hours biological process that endogenously, entrainable oscillation, which adjust behavior and physiological activities to environmental changes. This involves daily rhythmicity such as regulation of sleep-wake cycles, feeding, body temperature, blood pressure, heart rate, hormone secretion, metabolism (including lipid metabolism), and many other biological functions.\(^{169,170}\) Our circadian clock is set by the brain’s suprachiasmatic nucleus, which interprets recurring external stimuli, and autonomous molecular networks in peripheral cells together. When circadian clock is disrupted or misaligned, multiple pathologies, including chronic inflammatory and metabolic diseases such as atherosclerosis could rise.\(^{171}\)

Some studies suggest a circadian oscillations of circulating counts of leukocytes, or at least immune cell numbers involved in atherosclerosis (Figure 4).\(^{172}\) Emerging evidence suggests that circadian rhythms play an important role in vascular function and health. Circadian rhythms not only influence systemic atherosclerosis mediators, including leukocytes and lipids, but also locally control cells within the vessel wall. Studies conducted
>15 years ago demonstrated the existence of a functional circadian clock in the vasculature. (173-175) It was found that among 330 genes, 5% to 10% of the transcriptome, exhibit circadian expression patterns in mouse aortae. (176) Circadian patterned genes include those related to the core molecular clock, lipid and glucose metabolism, protein folding, and vascular integrity.

VSMC from human carotid plaque exhibits lower amplitudes of mRNA expression levels of core clock genes compared to normal carotid smooth muscle cells from same donors. This rose a notion about the role of mismatching circadian gene expression patterns toward the central clocks in atherosclerotic vessels, that might play a role in plaque stability. (177) Some evidences showed that brain and muscle Arnt-like protein-1 (BMAL1)-dependent peripheral circadian clocks in immune cells have a role in inflammatory markers expression, such as C-C motif chemokine ligand 2 (CCL2). (178) Studies in atherosclerotic mouse models indicated the importance of the CCL2 and C-C motif chemokine receptor (CCR2) axis in early lesion development. CCL2 or its corresponding receptor CCR2 genetic deficiency leads to a reduction in lesion development with lower monocyte/macrophage content in the lesion. (179, 180) Indicate that the CCL2-CCR2 axis in atherogenesis as a result of mobilization and homeostasis of classical monocytes under steady state rather than their recruitment. (181) Circadian clock gene period 2 (PER2) deficiency promotes aortic endothelial dysfunction (182), which is the initial stage of lesion development.

We can conclude that circadian rhythmicity plays an important role in atherosclerosis progressive by influencing atherosclerotic plaque development, either by central clock or many peripheral clocks existed. Cell-intrinsic molecular clocks found in leukocytes, endothelial cells, macrophages and SMC have been identified to be linked to inflammatory processes underlying atherosclerotic lesion development. (183) A better understanding of the link between circadian rhythms and cardiovascular pathologies might help developing more targeted and personalized therapeutic strategies for cardiovascular disease patients.

Gut Microbiota in Atherosclerosis

New and emerging technologies are continue to reveal that the microbiome plays a critical role in the maintenance of vascular health and in the development of vascular disease. The diversity of the human microbiome between individuals, in both species and patterns of colonization, may underlie the differential phenotypic expression of vascular disease and ultimately establish a new paradigm in personalized medicine. (184) The Human Microbiome Project used next-generation DNA sequencing to identify thousands of distinct bacterial species that are resident in and on the normal human body. The aggregate number of bacteria far exceeds the total number of human cells and accounts for 1% to 3% of the total body mass (i.e., 0.7-2.1 kg in a 70-kg person). DNA sequence analysis also revealed that microbes residing
in different anatomic sites such as the gut, skin, respiratory tract and genitourinary system are characterized by distinct enzymatic pathways that are adapted to metabolize nutrients present in the local environment.(185)

To understand the mechanisms by which the microbiome regulates vascular function, metabolomic profiling was used to identify specific bacteria-derived molecules related to energy metabolism and vascular homeostasis. Further analysis identified trimethylamine as the gut metabolite and bacteria-derived chemical with the clearest association with cardiovascular disease.(186) In clinical studies, unbiased metabolic profiling further revealed a significant increase in the levels of trimethylamine-N-oxide (TMAO) and related metabolites in plasma samples from patients with increased risk for CVD compared with matched control subjects.(187) TMAO is formed by bacterial metabolism of choline and phosphatidylcholine in the gut to yield trimethylamine, which is oxidized in the liver by the enzyme flavin monooxygenase-3 to form TMAO. (187) TMAO has become the target of several therapeutic interventions, ranging from schemes to reduce dietary intake of trimethylamine precursors to manipulations of the gut microbiome to reduce trimethylamine synthesis. The revelation regarding atherosclerosis susceptibility that could be transmitted from an atherosclerosis-prone strain of mice to another strain typically resistant to atherosclerosis simply by the transplantation of gut microbes provided additional causal evidence to support the role of the gut microbiome in regulating atherosclerosis (Figure 5).(188)

Studies of the gut microbiome in rodent models show that in response to changes in dietary intake of carbohydrates, fat, and fiber, there are changes in the gut microbiota at the phylum level. Similar studies in humans have shown the same trend, but there is significant interindividual variability. There is also regional variability in the microbiome, and the diversity and composition can reflect an industrialized versus agrarian diet. Thus, it may be possible to predict disease risk vis-à-vis diets rich in phosphatidylcholine, a source of choline, or dietary carnitine, which is ultimately metabolized to TMAO.(189)

At present, the causal pathways and molecular mechanisms whereby the gut microbiome initiates and perpetuates cardiopulmonary vascular disease remain incompletely characterized. However, early studies in the field indicate that future in vitro and in vivo studies of the blood vessel function must now contend with an additional layer of complexity in experimental design. These studies will need to examine local and remote interaction with the gut microbiota and metabolites. For in vitro studies often done in the presence of antibiotics, this remains a challenge. Further adding to the experimental complexity, the microbiome may be altered by diet and by drugs. Thus, in addition to standardizing diets for in vivo studies, the effects of drugs (and delivery vehicle) will need to be evaluated. (184)

**Gut Microbiota in Atherosclerosis**

Cell senescence describes the irreversible inability of a previously proliferative cell to proliferate, despite adequate mitogen stimulation. Cell senescence is a fundamental
process underlying normal biological ageing and aged-related degeneration of multiple tissues. However, recent studies have identified that cell senescence is also part of normal tissue remodeling, for example during development, as a process that regulates tissue mass and architecture.(190) Cellular senescence induces an evolutionarily conserved senescence-associated secretory phenotype (SASP), resulting in release of inflammatory cytokines, chemokines and proteases.(191) The SASP may be beneficial, for example attraction of immune cells to clear senescent cells (192-195) and tumor suppression (196,197). However, a persistent SASP may be deleterious, promoting cell proliferation (197), angiogenesis through increased vascular endothelial growth factor (VEGF) expression (198), epithelial-to-mesenchymal transformation and invasiveness of premalignant epithelial cells (199). The role of the SASP in atherosclerosis remains largely unknown, although the SASP of human senescent VSMCs requires interleukin (IL)-1α, and causes both endothelial cell dysfunction and mononuclear cell recruitment (200).

Telomere erosion in endothelial cells is increased in vessels prone to develop atherosclerosis (201,202), and the telomeres are shorter in VSMCs in human plaques compared with non-atherosclerotic vessels from the same donor (203). However, telomere shortening is not just a marker of senescence, but also promotes senescence, plaque development and features of unstable plaques. For example, telomere uncapping in VSMCs by forced expression of a dominant-negative telomeric repeat-binding factor 2 (TRF2) protein accelerates atherogenesis, increases necrotic core and reduces fibrous cap areas.(204) This suggests that dysfunctional telomeres predispose to both initiation and progression of atherosclerosis.(205) The effects of cell senescence in atherosclerosis clearly depend upon the cell type being affected. Senescent endothelial cells also accumulate in vessels with age (202,206) and in atherosclerosis (207,208), which may importantly contribute to age-accelerated atherogenesis. Senescent endothelial cells are dysfunctional and have reduced and uncoupled endothelial NO synthase (eNOS) activity, resulting in enhanced superoxide anion production and decreased NO bioavailability.(208,209) Senescent endothelial cells also exhibit increasing inflammatory responses, which include enhanced expression of vascular cell adhesion molecule-1 (VCAM-1) and intercellular adhesion molecule-1 (ICAM-1) (208,210), and also develop a SASP characterized by increased IL-6 and IL-8. Senescence, eNOS uncoupling and the SASP are regulated in part by p38a mitogen-activated protein kinase (MAPK), S6-kinase (S6K) and arginase II (211).

The senescence markers include elevated senescence-associated β-galactosidase (SA β-Gal) activity and p16Ink4a, p53 and p21 expression.(208,212) However, whether and how senescent cells contribute to atherogenesis remains unclear.(213,214) Human plaques contain cells with shortened telomeres, which predispose cells to undergo senescence.(204) Consistent with a proatherogenic role of senescence, the expression of a loss-of-function TRF2 in VSMCs accelerates plaque growth in the ApoE−/− mouse model of atherosclerosis, although in vivo evidence for increased senescence in plaques was not provided. (215) Importantly, senescent cells are metabolically and synthetically active, producing numerous factors that are released locally called senescence-messaging secretome or senescence-associated secretory phenotype. Interestingly, plasminogen activator inhibitor-1 (PAI-1) has been identified as a prominent member of the senescence-messaging secretome.(214) PAI-1 is a validated marker of cellular senescence (Figure 6).

PAI-1 is not a mere marker of cellular senescence but also a key mediator of cellular senescence and a major contributor to the multi-morbidity of aging.(216) The almost ubiquitous presence of cell senescence in atherosclerosis and the fundamental role of senescence in regulating plaque development and stability suggest that prevention or amelioration of senescence in atherosclerosis is a viable therapeutic target.(190)

![Figure 6. Molecular involvement of PAI-1 (plasminogen activator inhibitor-1) in cellular senescence and associated diseases.](image)
Coronary artery disease (CAD) has important genetic underpinnings considered equivalent to that of environmental factors. The heritability of CAD has been estimated between 40% and 60%, on the basis of family and twin studies, a method that yields high precision despite potential bias.(10) Precision medicine is an approach to disease treatment and prevention that seeks to maximize effectiveness by taking into account individual variability in genes, environment and lifestyle. One central aim of the recently launched US Precision Medicine Initiative is the return of genetic results for clinical utility.(217) The major clinical and biochemical atherosclerosis risk factors for coronary heart disease (CHD) and other forms of CVD have been well defined over the past 50 years by prospective population cohorts like the Framingham Heart Study and resulting randomized, controlled treatment trials (RCTs). Genetics for CVD risk prediction provides the opportunity to more precisely identify individuals at high risk for developing disease for whom preventive therapy can be directed.(218)

Our initial understanding regarding genetic risk for myocardial infarction and other forms of CHD has focused on rare (<1:100 carrier rate) monogenic etiologies conferring exceptional risk, such as mutations in genes LDLR, proprotein convertase subtilisin/kexin type 9 (PCSK9), or ApoB underlying the predisposition for familial hypercholesterolemia.(219-222) However, because of the efforts of international consortia over the past decade, genome wide association studies of hundreds of thousands of research participants have led to the discovery of more than 50 common (>1:20 carrier rate) gene variants with strong evidence for modest increases in CHD risk, and >150 common genetic variants with strong evidence for modest alterations of levels of key lipid fractions.(223) An individual’s CHD genetic risk score (GRS) is an additive score of the burden of discovered CHD risk alleles that is often weighted by the estimated disease effect of each allele.

Nevertheless, in a recent post hoc analysis of RCTs of statin therapy for primary and secondary prevention of CHD, persons with the highest burden of CHD risk alleles were not only at increased risk for CHD events, but also, surprisingly, experienced enhanced absolute and relative clinical benefit despite similar LDL-cholesterol lowering. (224) These data suggest that a CHD GRS may identify people at increased risk who may be more likely to benefit from preventive interventions.

The evidence of CHD not only affected by environmental factors, genetics factor play an important role as rising the risk to 2- until 3-fold in one’s personal with parental history of premature CHD.(225) Some observational epidemiological studies showed that plasma LDL (assessed as LDL-C and TRLs), HDL (assessed as HDL-C), triglyceride-rich lipoproteins (TRLs), and Lp(a), all been found to be correlated with CHD risks.(226-228)

About one half of the interindividual variation in plasma lipid concentrations attributable to genetic variants.(229) Lp(a) is an LDL-like particle that is covalently linked to a protein called apolipoprotein(a). Lp(a) level in plasma could varies up to 1000-fold determined by genetic variation.(230) Mendelian randomization studies found that genetically elevated Lp(a) results in increased risk of CHD.(231,232) Then, it was suggested that decreasing plasma Lp(a) may have a cardiovascular protective effect.

Lipoprotein-associated phospholipase A2 (Lp-PLA2) is an enzyme that is encoded by the phospholipase A2 group VII (PLA2G7) gene. Circulating Lp-PLA2 in plasma primarily associated with LDL particles, and thus its mass and activity is also associated with CHD risk.(233) Darapladib, an inhibitor of Lp-PLA2 in Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy (STABILITY) trial and The Stabilization Of PLaques using Darapladib-Thrombolysis In Myocardial Infarction 52 Trial (SOLID TIMI 52) found that darapladib did not reduce the risk of CHD (234,235), dubious the Lp-PLA2 as a causal risk factor for disease.

CHD follow-up studies have demonstrated roles for many other genes involved in CHD. Lysosomal acid lipase A (LIPA), sortilin 1 (SORT1) and tribbles homolog 1 (TRIB1) act as plasma lipid regulators in the liver, as well as in macrophages biology. Transcription factor 21 (TCF21) within the vessel wall is upregulated in dedifferentiated smooth muscle cell, migrate to form fibrous cap. Adamts7 is also a regulator of smooth muscle migration but also suggested to role the endothelial cells (Figure 7).(236)

The past decade of research has provided a broader understanding of the genetic architecture of CAD and demonstrates that the genetic basis of CAD largely derives from the cumulative effect of multiple common risk alleles individually of small effect size rather than rare variants with large effects on CAD risk. Although traditional risk factors remain important, application of these data using a systems genetics approach has pointed to substantial roles for genes and pathways relevant to vessel wall biology and immune function.(10)
Cardiovascular system homeostasis is sustained by the genetic and epigenetic interacting programs. Any disequilibrium will cause a complex stream of pathogenesis such as atherosclerosis and its life-threatening complications, myocardial infarction and stroke. Atherosclerosis is a chronic inflammatory disease that is initiated by the retention and accumulation of cholesterol-containing lipoproteins, particularly low-density lipoprotein, in the artery wall. In the arterial intima, lipoprotein components that are generated through oxidative, lipolytic and proteolytic activities lead to the formation of several danger-associated molecular patterns, which can activate innate immune cells as well as vascular cells. Moreover, self- and non-self-antigens, such as ApoB and heat shock proteins, can contribute to vascular inflammation by triggering the response of T and B cells locally. This process can influence the initiation, progression and stability of plaques. There are several uncertainties and challenges about the role of genetics in the management and prevention of chronic disease. The focus on precision medicine aims to catalyze an effort to better understand human disease biology, and optimize disease treatment and prevention by using a combination of clinical, biochemical, and genetic factors.

References


69. Martin SE, Williams N, Chatterjee S. Lactosylceramide is required in apoptosis induced by N-Smase. Glycoconj J. 2006; 23: 147-57.


